Some pharmaceutical companies have interesting stocks. Among them, PaxMedica, Inc. (Nasdaq: PXMD) has some promise because it is seeking treatments to moderate the symptoms of neurodivergent disabilities, which currently have no FDA-approved treatments. Its drugs are only tested on animal models, which is still far from the market launch. That being said, PXMD intends to submit an IND to the FDA in 2024, which, if approved, may end up being a major catalyst for PXMD stock.
PXMD Stock News
As of this writing, PXMD is working on treatments for Autism Spectrum Disorder (ASD), Fragile X Associated Tremor/Ataxia (FXATS), and African Sleeping Sickness (HAT). PAX 101 is an intravenous treatment for ADS, FXATS, and HAT.
PXMD stock’s next major research-related catalysts are PAX 101 phase 2B results and PAX 101’s IND. PAX 101 is currently in its phase 2B trial for ASD. Additionally, PAX 101 is in phase 3 trials for HAT, the results of which are set to be released in the second half of 2023. If the phase 3 results are favorable, it might positively catalyze the stock. PXMD plans to submit its PAX 101 IND in 2024, assessing whether treatments are safe for human trials. The IND process is not long and arduous; it usually takes 30 days for the FDA to reach a consensus concerning an IND, which is quick. If PAX 101 passes its IND process, then PXMD can conduct human trials.
IND, and medical jargon aside, PXMD stock has another potential catalyst in store. The stock has a history of short squeezes due to its unusual support. Not all supports are created equal. Some are brittle, while others endure constant retests, rarely breaking under pressure. Others, like PXMD Stock’s fabled $1.36 support, are nearly impregnable and cause multiple stock runs that exceed 100%. Currently, the stock is loaded with shorts and nearing that aforementioned support. PXMD’s short interest is 32.3%, 43.3% of its float is on loan, and its utilization is 100%. PXMD traders will likely buy in mass when the stock reaches the trendline causing a short squeeze, which will cause a run.
PXMD Stock Financials
According to its 2022 annual report, PXMD increased its assets significantly from $648 thousand in 2021 to $2.2 million in 2022. Its liabilities also decreased substantially from $10.7 million to $2 million. Increased trials increased its operating expenses from $7 million to $10 million. As a result, PXMD’s net loss increased from $6 million to $8 million.
Media Sentiment
@_andrewsoper is keeping his eyes on $PXMD
Technical Analysis
PXMD is in a bearish trend, in a downward channel below the 200 MA. It’s currently above the 50 and 21 MAs as well. The RSI is neutral at 56, and the MACD is reaching a bearish crossover. The stock is currently trading near its trend line support.
PXMD is in a bearish trend, in a downward channel below the 200 MA. It’s currently above the 50 and 21 MAs as well. The RSI is neutral at 56, and the MACD is reaching a bearish crossover. The stock is currently trading near its trend line support.
Given the stock’s history with short squeezes, it’s safe to assume that a short squeeze may occur at its $1.36 support. A possible play could be to go long and enter at the trend line support retest and TP at the 21 MA, 200 MA, and its $1.88 resistance. A stop loss could be set at around $1.31, indicating a break in the trend line support.
PXMD Stock Forecast
PXMD could experience a run due to its phase 3 HAT trial and PAX 101 IND. Given that information and the strength of its support, it is safe to assume that PXMD stock has a devoted following. Currently, the stock is trading near its trend line support, with a 32% short interest, which is why, given the history of PXMD stock, it will likely experience a short squeeze when it retests its support. Its $1.36 support caused the stock to run more than 100% three times in the past. This time may not be any different.
If you have questions about PXMD stock and where it could be heading next feel free to reach out to us in our free alerts room!
Disclaimer
Please visit and read our disclaimer here.
